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ABSTRACT
Introduction. Assisted Reproduction Technologies are in rapid development and implementation of 
preimplantation genetic testing (PGT) has allowed patients with genetic disorders to initiate 
pregnancies while minimizing or eliminating the risk of transmitting these disorders to their offspring. 
Testing for numeric chromosomal anomalies has been proposed as a way to increase efficacy in 
assisted reproduction, however this remains disputed. Legislation is lagging behind the rapid 
developments in this field. Material and methods. We conducted a structured online survey of 
legislation and accessibility to Preimplantation Genetic Testing in the Nordic countries to compare the 
regulation and uptake of this technique. The survey was designed and answered by the authors. 
Results. Key elements in regulation of preimplantation testing for monogenic disorders and structural 
rearrangements are similar in the Nordic countries although accessibility varies since only Denmark, 
Finland and Sweden have national clinics offering treatment. In addition, Denmark and Finland have 
private clinics offering PGT. Regulation is most stringent in Norway where a national board evaluates 
all couples seeking treatment. Treatment volumes vary between the Nordic countries with Norway 
and Finland having lowest treatment numbers. Preimplantation genetic testing for aneuploidy in the 
embryo varies between the Nordic countries where Finland and Iceland are allowed to offer this form 
of treatment, Denmark and Sweden only in the form of a research protocol while this form of testing 
is not allowed at all in Norway. Therefore the number of treatment cycles involving testing for 
embryo aneuploidy are lower in the Nordic countries compared to other countries where this 
treatment option is more common. Conclusions. Science needs to inform politics regarding the 
rapidly evolving field of reproductive medicine and we recommend harmonization of legislation and 
accessibility between the Nordic countries.
Keywords
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Abbreviations
PGT-A preimplantation genetic testing for aneuploidies
PGT-M preimplantation genetic testing for monogenic disorders
PGT-SR preimplantation genetic testing for structural rearrangements
ART assisted reproductive technologies
HLA human leukocyte antigen 
Key Message
We report the status of preimplantation genetic testing legislation and accessibility in the Nordic 
countries. The uptake of preimplantation genetic testing varies between the Nordic countries. 
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INTRODUCTION
A major breakthrough in the field of assisted reproduction was the introduction of preimplantation 
genetic testing (PGT) or preimplantation genetic diagnosis (PGD) as the technique was originally 
termed.1 This involves removing one or more cells from a preimplantation embryo to test for a genetic 
disorder with the goal of establishing an unaffected pregnancy. Sex determination of embryos from 
couples at risk of transmitting X-linked disease was the first clinical PGT-application, but the 
technology soon evolved to include analysis for monogenic disorders (PGT-M) and structural 
rearrangements (PGT-SR). Further developments have allowed for simultaneous human leukocyte 
antigen (HLA) testing in order to identify unaffected embryos which could also be an HLA-
compatible source for stem cell transplantation for a sibling.2 PGT is also possible if an individual, 
who may be at-risk for a late onset disease such as Huntington’s disease, wishes to prevent the birth 
of a carrier child without knowledge of their own carrier status. In these cases, it is possible to avoid 
alleles from the diseased family member, thus preserving the individual’s right not to know.3 The 
most recent development in the field involves non-invasive PGT (niPGT) where DNA fragments from 
the blastocyst fluid and culture media are analyzed in order to predict the chromosomal status of the 
embryo.4
Soon after the introduction of PGT for diagnosis of known genetic disorders, the use of the same 
technology to increase the efficacy of assisted reproductive technologies (ART) was suggested.5 
Aneuploidy, i.e. deviations in the numerical chromosome constitution of cells is found in a significant 
proportion of preimplantation embryos, occurring with an increasing frequency according to female 
age, reported from less than 30% in women < 30 years old to 80-90% in women above 40 years.6,7 
Selection of euploid embryos for transfer was thereby suggested as a possible way to improve clinical 
outcomes in ART especially for indications such as advanced maternal age, repeated implantation 
failure and recurrent miscarriage. The first pregnancies using PGT for this purpose (now termed PGT-
A) were soon reported.8 However, the first version of PGT-A based on biopsy of cleavage stage 
embryos using fluorescence in situ hybridization (FISH) for diagnosis was later shown to be 
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an attractive proposition in light of the issues mentioned above. Recent implementation of diagnostic 
techniques allowing comprehensive chromosome screening combined with trophectoderm biopsy at 
the blastocyst stage is expected to increase the effectiveness of PGT-A, but still its routine use is not 
unanimously recommended.10 Recent studies have shown that PGT-A may not improve overall 
pregnancy outcomes,11 so the technique remains disputed. Nevertheless, despite the lack of conclusive 
evidence, and the technical and cost-effectiveness aspects, the use of this technique is increasing 
although the uptake of PGT-A varies greatly internationally. In the USA, around 40% of in vitro 
fertilization cycles include PGT-A.12
In summary, PGT is used either as a diagnostic tool to identify embryos with genetic errors as an 
alternative to prenatal diagnosis in families with a known risk of a child with a monogenic disorder 
(PGT-M) or a structural rearrangement (PGT-SR), or for screening of embryos for aneuploidy (PGT-
A) in connection with infertility treatment to improve pregnancy rates and reduce the risk of 
miscarriage. In addition, the analytical genetic technology has evolved rapidly during the three 
decades since the introduction of PGT.
While technological advances improve our possibilities to offer new treatment modalities to our 
patients and improve outcome and efficacy, legislation often lags behind and new technology is often 
disputed. At the same time, PGT is subject to considerable variation in regulation between countries 
internationally.13 This is also the case between the Nordic countries.
The aim of the current study was to show the current status of PGT in terms of legislation and 
accessibility in the Nordic countries, representing a region being seemingly homogeneous with 
respect to culture, economy and access to public health care. 
MATERIAL AND METHODS
The study was performed as an on-line survey (SurveyMonkey) developed and approved by the 
authors in order to retrieve standardized information on legal aspects, reimbursement, accessibility, 
national treatment types and annual cycle numbers (see Supporting Information Table S1) in each of 
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Norway, and Sweden and all either work in clinics performing PGT (Denmark, Sweden and Norway), 
or have specific knowledge and experience related to referral for treatment in other countries (Norway 
and Iceland). Considering that the authors represented the available expertise and that none of the 
authors had any conflicts of interest, as the information provided is objective, the survey questionnaire 
was distributed by e-mail to the authors.
Ethical approval
Ethical review board approval for the study was not relevant because of the nature of the study.
RESULTS
Legal aspects
PGT-M and PGT-SR are allowed in all the Nordic countries. The same applies for PGT with HLA 
testing, although in Norway, Sweden and Denmark this is allowed on a case by case basis only with 
each case to be approved separately by a national board of health and welfare (Table 1). PGT-A is 
allowed unconditionally in Iceland and Finland only, but within a research protocol approved by a 
local ethics’ committee also in Denmark and Sweden. PGT-A is not allowed in Norway (Table 1). 
PGT is allowed also in privately funded clinics in all Nordic countries except in Norway. No clear 
distinction is made regarding the forms of PGT allowed in the privately funded clinics.
In Denmark, PGT-M/SR can be offered whenever prenatal diagnosis can be accepted, i.e. in couples 
with a high risk of transmitting a severe genetic disorder. The risk level is not clearly defined, but 
essentially greater than 25%. Severe disease is also not clearly defined. Initially, it was attempted to 
elaborate a “positive” list, but this was not possible due to many reasons such as variable expressivity 
of the disorder leading to variable phenotype and lack of agreement on the definition of what really is 
a severe disease.
In Finland, the situation is similar to Denmark in that PGT-M/SR can be offered where prenatal 
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In Sweden PGT-M/SR is allowed if the male or female is carrying a mutation or a structural 
chromosomal aberration with a high risk of a child with of a serious disease 
In Norway and Iceland, PGT-M/SR is allowed but not practised, and a low number of patients are 
referred each year for PGT-M/SR abroad (see below).
In Norway, all couples need to be approved by the National Office for Health Service Appeals, a 
government agency subject to the Norwegian Ministry of Health and Care Services. If the monogenic 
disorder is expected to lead to a “normal” life or if the disease is “treatable” the application will be 
rejected.
PGT-M and PGT-SR are publicly funded in all Nordic countries, and so is PGT for HLA matching, 
except in Iceland. In Norway and Iceland where PGT is not performed, PGT treatment in clinics 
abroad is publicly funded – except for the HLA analysis in PGT-HLA for Icelandic couples. Sex 
selection is allowed in Iceland, but not performed. Sex selection is allowed in case of X-linked disease 
in Denmark, Sweden and Finland, but not for family balancing.
Treatment is currently offered within the public health care system for two healthy children in 
Sweden, Norway, Finland and Denmark. However, this is not regulated by legislation. There are no 
limits for treatment in Iceland.
Treatment activity
PGT is not performed in Norway and Iceland. Three public clinics in Denmark, two in Sweden and 
one in Finland are performing PGT. One private clinic in Denmark and four in Finland offer PGT 
(Table 3). More than 300 PGT-M and PGT-SR cycles are performed yearly in Denmark and Sweden 
respectively, and 70-100 in Finland, whereas from Norway less than 50 and from Iceland 5-10 PGT-
M and PGT-SR cases are sent abroad yearly (Table 4, data from 2018). From Norway, about 35 
couples are referred to Sweden every year for PGT-M and PGT-SR. The number of patients from 
Norway is lower than in the other Nordic countries due to more strict criteria.
No PGT-A is offered to couples in Norway and Sweden, whereas 50-100 PGT-A cycles are offered to 
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available on PGT-A cycles for Danish, Finnish, Icelandic and Swedish patients being performed in 
other countries.
DISCUSSION
The present survey shows some similarities between the Nordic countries, but also a striking 
diversity.
PGT for monogenic disorders and structural chromosomal aberrations are allowed in all countries, but 
not performed in Norway and Iceland, from where candidates are sent abroad. Currently however, 
preparations are ongoing in both countries to start offering PGT locally. Family balancing by sex 
selection is not performed in any of the Nordic countries and is not allowed in Denmark, Sweden, 
Norway or Finland. PGT-M and PGT-SR is publicly funded in all countries.
The number of PGT-M and -SR cycles offered to Danish patients seems to be double the number 
performed per inhabitant compared to Sweden and Iceland. Also, the numbers seem low in Finland, 
although increasing, and very low in Norway. The trend in all countries is that PGT is performed in 
very few centers, presumably because of the high technical demands and the requirements for 
extensive genetic counseling to patients. When performing PGT for genetic disorders, a clinical 
geneticist will in many cases need to study the penetrance of the disorder in the couple’s immediate 
family and all patients require counseling regarding interpretation of outcome of the analysis and the 
chances of having a non-affected child. PGT-M/SR is also offered in private clinics in Denmark and 
Finland. Legal limitations do not seem to fully explain the rather low PGT-M and PGT-SR activity in 
Norway and Finland although the Norwegian legislation is more strict than in the other Nordic 
countries. Lack of availability and access to treatment may also explain lower numbers of PGT-M/SR 
in Norway and Iceland. Problems stemming from very restrictive legislation in PGT have been 
documented as it is considered to be at odds with both reproductive autonomy of patients, established 
international practice and also to treat different indications and varied penetrance of disorders 
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The differences between countries regarding the number of PGT-M and PGT-SR cycles are difficult 
to explain but may not only be partly due to legal limitations but also to differences in awareness of 
this alternative to prenatal diagnosis as well as differences in resource allocations and reimbursement 
policies.
Most Western European countries have some restrictions on the use of PGT and regulate this activity 
through legislation. Typically PGT-M/SR is limited to cases of serious hereditary disease and in some 
countries, such as France, a case by case approval by a multidisciplinary committee is required. In 
other countries, such as the UK, general specifications are in force for the conditions under which 
PGT can be performed and each new disease has to be approved by the Human Fertilization and 
Embryology Authority (HFEA). PGT-A is allowed in many Western European countries whereas 
access to state funded treatment, which in general is high in the Nordic countries, might reduce patient 
pressure for performing PGT-A. The situation in Europe is very different from the US where no 
regulation on the application of PGT exists.15 To a certain extent, variation in legislation between 
countries causes reproductive tourism, i.e. couples or individuals seeking treatment which is not 
permitted or accessible in their home country.13 PGT-A is unconditionally allowed in Finland and 
Iceland only, but performed within research protocols in Denmark and Sweden. Overall PGT-A has 
very limited use in the Nordic countries seen as a proportion of the national ART activities: in 2014 
the total number of in vitro fertilization and frozen/thawed embryo transfer cycles in these countries 
was 54 653.16 This is in striking contrast to the situation in many other countries where a large 
proportion of in vitro fertilization cycles are performed with PGT-A.17 The development of the 
diagnostic techniques such as complete genome sequencing, enables uncovering more genetic 
information than the specific genetic problem requiring PGT.18 For example massive parallel 
sequencing allows complete genome sequencing. Presently massive parallel sequencing is used for 
PGT-A and also for PGT-SR where concomitant diagnosis of structural errors and chromosome 
number is delivered as extra information. In this respect, legislation which restricts the use of PGT-A 
is not in harmony with the technical advances of the last few years. In fact the arbitrary and technical 
distinction between these two PGT modalities is gradually vanishing as genome-wide single 
nucleotide and copy number variation (SNV and CNV) genetic laboratory testing is being carried out 
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doubt that biologically, PGT-A should be efficient. However, the rather disappointing results of 
recent, larger prospective, randomized multicenter studies may be a reason to reconsider the 
implementation of large-scale PGT-A in ART, at least to selected patient groups.20, 21 Nevertheless 
with the use of blastocyst culture often only a few blastocysts are usually available for transfer, and at 
the end of the day – after transfer of all blastocysts – the euploid embryo (if any) will be identified by 
implantation and establishment of a pregnancy. The balance between costs for PGT-A versus 
successive transfers has not been investigated in a public health care environment with a 
reimbursement system allowing for cumulative transfers of all embryos from one oocyte pick up. 
Beyond doubt, the cumulative pregnancy rate per initiated cycle will be little – if at all - improved. 
This may well contribute to the low use of PGT-A in the Nordic countries given the relatively easy 
access to state funded treatment. However, in certain patient groups it may be of value, for example 
PGT-A may allow identification of embryos with viable trisomies in selected couples. It may also 
function as a ranking of embryo potential, in addition to morphology and development, shortening 
time to pregnancy and live birth,22 at least for patients with a high number of good quality embryos.
Massive parallel sequencing technology has increased the utilization possibilities of PGT together 
with promising developments in the use of non-invasive PGT on cell-free DNA from blastocyst fluid 
and spent media.4, 23, 24
The next big step in PGT will probably be the large scale introduction of non-invasive embryo 
analysis techniques, where the potential for improvements in outcome and reduction in costs is 
great.23, 21 Additionally, preconception carrier screening for selected Mendelian recessive diseases is 
emerging,25 and when implemented on a larger scale, this will increase the need for preimplantation 
genetic testing and prenatal diagnosis. Whether the strict legislation regarding PGT-A in some 
countries will change following implementation of non-invasive techniques remains to be seen.
CONCLUSION
We have shown the greatly varied uptake of PGT technology and its application in the Nordic 
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We also see the need for science to inform politics since legislation in our swiftly developing field is 
lagging behind. To increase equality in access to this new technology, and to some extent counteract 
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Tables
Table 1. Types of preimplantation genetic testing allowed in the Nordic countries. 











Iceland Yes Yes Yes Yes Yes Yes Yes










































The table specifies the types of preimplantation genetic testing (PGT) for aneuploidies (PGT-A), monogenic disorders 
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Table 2. Reimbursement for preimplantation genetic testing if performed in clinics in other countries?
Iceland Yes, for PGT-M and PGT-SR
Sweden No
Norway Yes, for PGT-M, PGT-SR and PGD-HLA
Denmark Some treatments have been publicly funded after special application
Finland No
The table specifies if and to which extent treatments are funded for preimplantation genetic testing (PGT) internationally. 
M (monogenic disorders), SR (structural chromosomal rearrangements), HLA (human leukocyte antigen, i.e. tissue 
histocompatibility testing).







The table shows the number of public and private clinics in the Nordic countries offering preimplantation genetic testing 
(PGT). In Finland four private clinics offer for aneuploidies (PGT-A),  monogenic disorders (PGT-M), and structural 
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0 >300 30 1897
Norway
5.3 million
0 35 (abroad) 6.6 2054
Denmark
5.6 million
50-100 >300 54 2884
Finland
5.5 million
100-200 70-100 18 1566
The table specifies the number of cycles of preimplantation genetic testing (PGT) cycles per year, M (Monogenetic 
disorder), SR (Structural Chromosomal Rearrangements). Data from 2018. Total number of fertility treatment cycles in 
these countries is included for comparison.16
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